ABCC4 | ATP-binding cassette, sub-family C (CFTR/MRP), member 4 | Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
AQP1 | Aquaporin 1 (Colton blood group) | Blood group antigen proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
AQP10 | Aquaporin 10 | Predicted membrane proteins Transporters
| | | | | Group enriched |
AQP2 | Aquaporin 2 (collecting duct) | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
AQP3 | Aquaporin 3 (Gill blood group) | Blood group antigen proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
AQP4 | Aquaporin 4 | Predicted membrane proteins Transporters
| | | | | Group enriched |
AQP5 | Aquaporin 5 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
AQP6 | Aquaporin 6, kidney specific | Predicted membrane proteins Transporters
| | | | | Tissue enriched |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CATSPER4 | Cation channel, sperm associated 4 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
CD47 | CD47 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DERL2 | Derlin 2 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DRAM1 | DNA-damage regulated autophagy modulator 1 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DRAM2 | DNA-damage regulated autophagy modulator 2 | Predicted membrane proteins
| | | | | Mixed |
JKAMP | JNK1/MAPK8-associated membrane protein | Cancer-related genes Predicted membrane proteins
| | | | | Expressed in all |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK1 | Potassium channel, subfamily K, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
PDE3B | Phosphodiesterase 3B, cGMP-inhibited | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PPAP2A | Phosphatidic acid phosphatase type 2A | Enzymes Predicted membrane proteins
| | | | | Mixed |
RP11-35N6.1 | Lipid phosphate phosphatase-related protein type 1 | Predicted membrane proteins
| | | | | Group enriched |
SCN2A | Sodium channel, voltage-gated, type II, alpha subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
SGMS2 | Sphingomyelin synthase 2 | Enzymes Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC12A5 | Solute carrier family 12 (potassium/chloride transporter), member 5 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
SLC1A5 | Solute carrier family 1 (neutral amino acid transporter), member 5 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC22A15 | Solute carrier family 22, member 15 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
SLC43A1 | Solute carrier family 43 (amino acid system L transporter), member 1 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SLC7A8 | Solute carrier family 7 (amino acid transporter light chain, L system), member 8 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
SPNS1 | Spinster homolog 1 (Drosophila) | Mitochondrial proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
TMEM165 | Transmembrane protein 165 | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Expressed in all |
TMEM229A | Transmembrane protein 229A | Predicted membrane proteins
| | | | | Tissue enhanced |
TRPM4 | Transient receptor potential cation channel, subfamily M, member 4 | Disease related genes Potential drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
TRPM5 | Transient receptor potential cation channel, subfamily M, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |